In medical research, especially in medical trials like those carried out by NZCR, it's important that people fully understand what a clinical trial involves, as well as the risks and benefits. So, before someone joins a clinical trial, NZCR must give potential participants all the details about the study.

Selarsdi, a biosimilar drug recently tested at NZCR for psoriasis and active psoriatic arthritis, has been granted approval for sale in 83 countries, including NZ. Thanks to all our participants for helping make this drug a reality, enabling access to millions more people worldwide. 

NZCR was recently involved in promising Phase-1 research of a new drug, TLC-2716, to treat people with severe high triglycerides and NASH. These promising early results, enables OrsoBio to move on to Phase-2a stage of testing with patients who have high triglycerides and liver fat.

Clinical trials are an incredibly important part of the process to bring new drugs to market and a participant’s safety is the number one priority in any clinical study.  Read about the safety protocols and checks completed throughout the trial process.

Clinical Trials Process

Before any new drug or medicine can be bought to market, the Sponsor or Developer must prove the drug does what it is intended to do, all side effects are known and understood, and it is safe for humans to take. This article outlines the clinical research processes and checks NZCR must follow to ensure trials are conducted safely and ethically.

Regulation of Clinical Trials

New Zealand Clinical Research (NZCR) undertakes clinical trials in NZ for many medical and pharmaceutical groups around the world. This must be done under strict regulatory controls to ensure the medical trial is conducted safely, ethically, and with scientific rigour. Learn about the meticulous review process NZCR must undergo before they can start trialing any new drug.

Many medical trial participants prefer participating in a biosimilar study because the medication has already been tested and approved. Biosimilar studies test new variants of an already approved drug and aim to prove that a newly created version is the same as an existing one.

They say “good things take time”, and never has that been more true than in the case of Trikafta, a new treatment for the symptoms of Cystic Fibrosis, now funded by Pharmac.

There is evidence that different ethnic groups may respond differently to certain treatments due to genetic and environmental factors. A lack of diversity in clinical trials in NZ can perpetuate health disparities and limit access to treatments for underrepresented groups.

New Zealand Clinical Research (NZCR) is a leading early-phase clinical research provider. Our expert research team has conducted over 750 clinical studies in NZ involving more than 15,000 New Zealanders. With facilities in Wellington, Hamilton, Christchurch, and Auckland, clinical trials are being conducted daily to test investigative medicines. For NZCR to do this research it needs healthy people and patients to join its research community.

NZCR, a top provider of clinical trials in NZ, was commissioned to run the world’s first ‘in-human’ trial of this Nobel prize winning technique.

NZCR's Professor Ed Gane is a world leading researcher. His recent research of Hepatitis B in Japanese and Non Japanese subjects has recently been published in Anti Viral Therapy

Get in touch today

NZCR Advancing global health